期刊文献+

^131I治疗甲亢604例近期疗效分析 被引量:4

下载PDF
导出
摘要 目的分析^131I治疗甲亢近期临床疗效。方法根据甲状腺质量和最高吸碘率等给予604例甲亢患者个性化^131I治疗,^131I于治疗后1、3、6、12个月随访,对甲亢、Graves眼病、甲亢性心脏病、低钾周期性麻痹、谷丙转氨酶升高、粒细胞减少及甲状腺大小等的转归进行回顾性分析。结果痊愈374例(61.9%),部分缓解101例(16.8%),甲减112例(18.5%),无效17(2.8%),总有效率为97.2%,治愈率为80.4%。^131I治疗Graves眼病总有效率83.7%,治疗甲亢性心脏病总有效率95.6%,同时可以缓解低钾周期性麻痹症状,改善肝功能,升高粒细胞,缩小甲状腺。结论^131I治疗甲亢及其伴发症安全有效,但要注意甲减等并发症的发生。 Objective To analyze the short - term clinical efficacy of ^131I therapy in hyperthyroidism. Methods 604 patients with hyperthyroidism were treated with individual ^131I therapy based on the quality and the highest thyroid iodine absorption rate, All patients were followed up for 1, 3,6 and 12 months after ^131I treatment, the outcome of Graves ophthalmopathy, hyperthyroidism heart disease, hypokalemic periodic paralysis, alanine aminotransferase increased, neutropenia and thyroid mass were analyzed retrospectively. Results Of the 604 patients, 61.9% (374/604) recovered, 16. 8% (101/604) were partial remission, 18.5% (112/604)were hypothyroidism, 2. 8% (17/604)were ineffective, total effective rate was 9% 2% , the cure rate was 80. 4%. ^131I treatment of graves eye disease had a total effective rate of 83.7% , total effective rate in treating hyperthyroidism heart was 95.6%, while periodic paralysis could relieve symptoms, improve liver function, elevated neutrophil and the decreased thyroid mass ( P 〈 0. 01 ). Conclusion ~31I therapy for hyperthyroidism is safe and effective, can be used as the preferred treatment, but the complications of hypothyroidism else must be considered.
出处 《浙江临床医学》 2010年第8期797-800,共4页 Zhejiang Clinical Medical Journal
关键词 甲状腺功能亢进症 ^131I治疗 甲亢性心脏病 GRAVES眼病 低钾周期性麻痹 甲状腺功能减退症 Hyperthyroidism ^131I radioiodine therapy Hyperthyroidism heart Graves ophthalmopathy Hypokalemic periodic paralysis Hypothyroidism
  • 相关文献

参考文献20

  • 1Bahn RS,Burch HS,Cooper DS,et al.The role of propylthiouracil in the management of Graves'disease in adults:report of a meeting joinfly sponsored by the american thyroid association and the food and drug administration.Thyroid,2009 Jul,19(7):673-674.
  • 2Mezosi E.Hyperthyroidism.Orv Hetil,2006 Jul,147(28):1309-1314.
  • 3王勤奋,张承刚,赵晓斌,施龙宝.1003例Graves病^(131)I治疗临床分析[J].中华核医学杂志,2005,25(2):108-110. 被引量:62
  • 4El-Kaissi S,Bowden J,Henry MJ,et al.Int association between radioiodine therapy for Graves'hyperthyroidism and thyroid-associated ophthalmopathy.Ophthalmol,2010 Apr 20.
  • 5Bartalena L,Pinchera A,Marcocci C.Management of Graves'ophthalmopathy:reality and perspective.Endocrine Rev,2000,21:168-199.
  • 6Acharya SH,Avenell A,Philip S,et al.Radioiodine therapy(RAI)for Graves'disease(GD)and the effect on ophthalmopathy:a systematic review.Clin Endocrinol(Oxf),2008,69(6):943-950.
  • 7Baldys-Waligórska A,Stefanska A,Golkowski F,et al.Evaluation of radioiodine1311 treatment in Graves'disease patients with mild orbitopathy.Przegl Lek,2009.66(4):166-169.
  • 8Metso S,Auvinen A,Salmi J,et al.Increased long term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism.Clin Endocrinol(Oxf),2008 Mar,68(3):450-457.
  • 9Kung AW.Clinical review:Thyrotoxic periodic paralysis:a diagnostic challenge.J Clin Endocrinol Metab,2006 Jul,91(7):2490-2495.
  • 10Shishiba Y,Nippon R.Recent progress on the searchs of pathogenesis of thyrotoxic periodic paralysis,2006,64(12):2339-2347.

二级参考文献33

  • 1党双培,潘裕持,姜兆凯.甲亢性肝病[J].甘肃医药,1995,14(2):80-81. 被引量:8
  • 2叶任高.内科学[M](第5版)[M].北京:人民卫生出版社,2002.392-402.
  • 3Tamai H, Mukuta T, Matsubayashi S, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab, 1993,77:1356 - 1360.
  • 4腾卫平 见:叶任高 陆再英 主编.甲状腺机能亢进症[A].见:叶任高,陆再英,主编.内科学[M]:第6版[C].北京:人民卫生出版社,2004.725-735.
  • 5Wartofsky L. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America. Thyroid, 1997.7: 213-216.
  • 6Lind P. Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med Mol Imaging, 2002, 29 Suppl 2: 453-457.
  • 7Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab, 1998, 83: 40-46.
  • 8Videla LA,Smok G,Troncoso P,et al.Influence of hyperthyroidism on lindane-induced hepatotoxicity in the rat.Biochem Pharmacol,1995,50(10):557
  • 9Anton Aranda E.Intrahepatic cholestasis in untreated hyperthyroidism.Rev Esp Enferm Dig,2000,2(1):9
  • 10Viallard JF,Tabarin A,Neau D,et al.Hyperthyroidism with severe intrahepatic cholestasis.Dig Dis Sci,1999,4(10):2001

共引文献220

同被引文献29

  • 1陈茹芬,罗剑彬,叶伟坚.甲亢性心脏病两种治疗方法临床疗效比较[J].中国现代药物应用,2009,3(6):96-98. 被引量:13
  • 2陈再君,蒋宁一.^(131)I治疗甲亢后致甲减的研究变迁[J].国外医学(放射医学核医学分册),2004,28(4):153-157. 被引量:20
  • 3El Kaissi S,Bowden J,Henry M J,et al.Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy[J].Int Ophthalmol,2010,30(4):397-405.
  • 4Mezosi E.Hyperthyroidism[J].Orv Hetil,2006,147(28):1309-1314.
  • 5Konrdy A.Radioiodine treatment of benign thyroid diseases[J].Orv Hetil,2006,147(37):1783-1789.
  • 6黄文盛 樊裕明 王昱豊.辐射与甲状腺.核子医学杂志,2000,13(3):175-180.
  • 7中华医学会核医学分会.甲状腺疾病133I治疗.临床技术操作规范·核医学分册[M].北京:人民军医出版社,2004:175-177.
  • 8Allahabadia A, Daykin J, Holder RL, et al . Age and gender pridict the outcome of treatment for Graves hyperthyroidism [J]. J Clin Endocrinol Metab ,2000,85(3): 1038-1042.
  • 9Metso S, Jaatinen P, Huhtala H, et al . Long-term follow-up study of radioiodine treatment of hyperthyroidism[J]. CAin Endocrinol , 2004,61 (5):641-648.
  • 10Bahn RS, Butch HS, Cooper DS, et al. The Role of Propyhhiouracil in the Management of Graves'Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration [ J ]. Thyroid, 2009,19 ( 7 ) :673 - 674.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部